Illustrative only
Competitive timeline
2 potential launches before Asset A (2029) · 1 the same year
Competitive timeline 2026 to 2031: the eleven programmes nearest to market, from a regulatory decision in 2027 to launches through 2031, filterable by phase, modality and mechanism.
Programmes by phase
Heart Failure pipeline by development stage: 46 preclinical programmes, 22 Phase I, 31 Phase II, 14 Phase III and 3 filed or approved. Selecting a stage filters the timeline.
116 active programmes in the indication.
Modality split
Pipeline modality split: small molecules are 54% of programmes, ahead of antibodies and biologics at 18%, RNA at 12%, cell or gene therapy at 9% and other modalities at 7%.
54% of the pipeline is oral – the archetype an add-on competes in on price.